Veradigm | MDRX - Cash And Equivalent


Veradigm reported $492.6M in Cash and Equivalent for its fiscal quarter ending in September of 2022.





Cash And Equivalent Change Date
Alcidion AUD 11.8M 2.84M Jun/2024
Ambu A/S DKK 691M 44M Mar/2026
Amplifon EUR 309.56M 673K Mar/2026
Cardinal Health USD 4.86B 919M Jun/2026
Centene USD 24.15B 2.89B Jun/2026
Charles River Laboratories USD 192.02M 195K Jun/2026
Cigna USD 6.3B 742M Jun/2026
Coloplast 911M 497M Sep/2023
Convatec Group USD 64.7M 32.2M Dec/2024
CVS Health USD 11.33B 1.79B Jun/2026
Diasorin EUR 173.08M 3.51M Jun/2025
Elevance Health USD 10.23B 575M Jun/2026
General Electric Aerospace USD 9.35B 1.64B Jun/2026
Gulf Medical Proj AED 74.52M 101.52M Mar/2025
Humana USD 6.89B 1.94B Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Laboratory Of America USD 141.8M 839.3M Jun/2026
Maximus USD 56.95M 100.5M Jun/2026
McKesson USD 5.16B 1.19B Jun/2026
Med Life RON 168.41M 16.94M Mar/2026
Molina Healthcare USD 4.99B 329M Jun/2026
Omnicell USD 292.16M 52.94M Jun/2026
Oriola-kd EUR 107.6M 13.9M Sep/2025
Owens Minor USD 7.65M 329.23M Jun/2026
Quest Diagnostics USD 626M 233M Jun/2026
Rede D'or Sao Luiz BRL 5.41B 1.7B Mar/2026
Siemens Healthineers EUR 1.91B 235M Mar/2026
Sonova Holding CHF 413.9M 134.3M Jun/2023
Supermax Corporation Bhd MYR 637.59M 217.66M Mar/2026
UnitedHealth USD 31.47B 239M Jun/2026
Veeva Systems USD 1.9B 475.35M Mar/2026
Veradigm USD 492.6M 7.57M Sep/2022
Xerox USD 495M 90M Jun/2026